| Wang Yunhan,Zheng Xiaoli,Sun Yanan,et al.Relationship between lung immune prognostic and the prognosis of locally advanced non-small cell lung cancer treated with radiochemotherapy[J].Chinese Journal of Radiological Medicine and Protection,2022,42(7):504-510 |
| Relationship between lung immune prognostic and the prognosis of locally advanced non-small cell lung cancer treated with radiochemotherapy |
| Received:January 19, 2022 |
| DOI：10.3760/cma.j.cn112271-20220119-00027 |
| KeyWords:Locally advanced non-small cell lung cancer Radiochemotherapy Prognostic indicator Lung immune prognostic index |
| FundProject: |
| Author Name | Affiliation | E-mail | | Wang Yunhan | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Zheng Xiaoli | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Sun Yanan | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Wang Xiaohui | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Luo Hui | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Cheng Chen | Department of Outreaching, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Yang Yang | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Dan Qinfu | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Ye Ke | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | | | Ge Hong | Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China | gehong666@126.com |
|
| Hits: 4235 |
| Download times: 1132 |
| Abstract:: |
| Objective To investigate the relationship between lung immune prognostic index (LIPI) and the prognosis of locally advanced non-small cell lung cancer (LA-NSCLC) treated with radiochemotherapy. Methods A retrospective analysis was conducted for the clinical data of LA-NSCLC patients who received radiochemotherapy in the Affiliated Cancer Hospital of Zhengzhou University from 2013 to 2019. According to the hematologic test result of the derived neutrophil-to-lymphocyte ratio (dNLR) and the lactate dehydrogenase (LDH), the patients were divided into three groups according to their LIPI scores, namely the good-LIPI group with dNLR ≤ 3 and LDH ≤ upper limit of normal (ULN), moderate-LIPI group with dNLR >3 or LDH > ULN, and poor-LIPI group with dNLR >3 and LDH > ULN. Moreover, the overall survival (OS) and the progression-free survival (PFS) were calculated using the Kaplan-Meier method, the Log-rank test, and the Cox regression model. Results A total of 238 patients were enrolled, and their median follow-up time was 37.1 months, median PFS 16.1 months, and median OS 30.6 months. The OS and PFS of the poor-LIPI group were significantly worse than those of the good- and moderate- LIPI groups (χ2= 9.04, 2.88, P＜0.05). The univariate analysis showed that the factors influencing OS included gender, pathological type, epidermal growth factor receptor (EGFR) mutations, and LIPI (χ2=6.10, 13.66, 10.58, 9.04, P＜0.05), and the PFS was only affected by the LIPI (χ2=2.88, P= 0.03). Multivariate analysis suggested that EGFR mutations and LIPI were independent prognostic markers for OS (HR= 1.31, 1.36; 95% CI: 1.03-1.67, 1.05-1.76; P＜0.05). Conclusions The LIPI is a potential prognostic indicator of radiochemotherapy in LA-NSCLC, and this result should be further confirmed by prospective studies. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
